5-甲基-4-异恶唑磺酰氯 | 321309-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基-4-异恶唑磺酰氯
• 中文别名: 5-甲基-4-异唑磺酰氯；5-甲基异恶唑-4-磺酰氯
• 英文名称: 5-methylisoxazole-4-sulfonyl chloride
• 英文别名: 5-methyl-4-isoxazolesulfonyl chloride；5-Methyl-isoxazol-4-sulfonylchlorid；4-chlorosulfonyl-5-methylisoxazole；5-methyl-1,2-oxazole-4-sulfonyl chloride
• CAS: 321309-26-6
• 化学式: C₄H₄ClNO₃S
• mdl: MFCD02681975
• 分子量: 181.6
• InChiKey: STYUNYVEEFPQMF-UHFFFAOYSA-N

物化性质

• 沸点：
  56-58°C 0,7mm
• 密度：
  1.534±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  68.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R34
• 海关编码：
  2934999090
• 危险品运输编号：
  UN 3261
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P280,P303+P361+P353,P301+P330+P331,P304+P340+P310,P305+P351+P338+P310
• 危险性描述：
  H314

SDS

Name:	5-Methyl-4-isoxazolesulfonyl chloride 95+% Material Safety Data Sheet
Synonym:
CAS:	321309-26-6

Section 1 - Chemical Product MSDS Name:5-Methyl-4-isoxazolesulfonyl chloride 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
321309-26-6	5-Methyl-4-isoxazolesulfonyl chloride	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 321309-26-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 56 - 58 deg C @0.7mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H4ClNO3S
Molecular Weight: 182

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 321309-26-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Methyl-4-isoxazolesulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, N.O.S.*
Hazard Class: 8
UN Number: 1760
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 321309-26-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 321309-26-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 321309-26-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-4-异恶唑磺酰氯 、 3-(哌啶-4-基)苯并[d]异恶唑 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以48%的产率得到3-[1-[(5-Methyl-1,2-oxazol-4-yl)sulfonyl]piperidin-4-yl]-1,2-benzoxazole
  参考文献：
  名称：

  利用原位生成的腈氧化物和芳烃的[3 + 2]环加成，对苯并异恶唑的各种文库进行固溶相合成

  摘要：

  苯并异恶唑的文库是通过腈与芳烃的[3 + 2]环加成反应合成的，并通过酰化/磺酰化和钯催化的偶联过程进一步多样化。八种关键中间体苯并异恶唑是通过在CsF存在下，邻-（三甲基甲硅烷基）芳基三氟甲磺酸酯和氯肟在温和的反应条件下以良好或优异的收率反应制得的。这些构件已被用作各种3,5,6-三取代的苯并异恶唑的关键组分。

  DOI：

  10.1021/co300159g

文献信息

• Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2
  作者：Moses Moustakim、Kerstin Riedel、Marion Schuller、Andrè P. Gehring、Octovia P. Monteiro、Sarah P. Martin、Oleg Fedorov、Jag Heer、Darren J. Dixon、Jonathan M. Elkins、Stefan Knapp、Franz Bracher、Paul E. Brennan

  DOI：10.1016/j.bmc.2018.03.020

  日期：2018.7

  unclear. A medium throughput screen led to the identification of N-(2(-9H-carbazol-1-yl)phenyl)acetamide (GeA-69, 1) as a novel allosteric PARP14 MD2 (second MD of PARP14) inhibitor. We herein report medicinal chemistry around this novel chemotype to afford a sub-micromolar PARP14 MD2 inhibitor. This chemical series provides a novel starting point for further development of PARP14 chemical probes.

  聚腺苷二磷酸核糖聚合酶14（PARP14）已牵涉到DNA损伤反应途径中的同源重组。PARP14包含三个（ADP核糖结合）宏域（MD），尚不清楚其对病理学中整个PARP14功能的确切贡献。中等通量筛选导致鉴定出N-（2（-9H-咔唑-1-基）苯基）乙酰胺（GeA-69，1）作为新型变构PARP14 MD2（PARP14的第二个MD）抑制剂。我们在此报告了围绕这种新型化学型的药物化学，以提供亚微摩尔的PARP14 MD2抑制剂。该化学系列为进一步开发PARP14化学探针提供了新的起点。
• [EN] COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF<br/>[FR] COMPOSÉS UTILES COMME MODULATEURS DE LA FAAH ET UTILISATION DE CEUX-CI
  申请人：RENOVIS INC

  公开号：WO2009011904A1

  公开（公告）日：2009-01-22

  Compounds are disclosed that have formula (I): where A, B, L1, X, W, Y, R1, R3, and nlare as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, anxiety, depression, inflammation, cognitive disorders, weight and eating disorders, Parkinson's disease, Alzheimer's disease, spasticity, addiction, glaucoma, and others.

  公开了具有通式(I)的化合物：其中A、B、L1、X、W、Y、R1、R3和n1如本文所定义。这些化合物及其药物组合物可用于预防和治疗包括人类在内的哺乳动物的各种病症，包括但不限于疼痛、焦虑、抑郁、炎症、认知障碍、体重和饮食障碍、帕金森病、阿尔茨海默病、痉挛、成瘾、青光眼等。
• THIAZOLYL PIPERIDINE DERIVATIVES
  申请人：Stieber Frank

  公开号：US20110105505A1

  公开（公告）日：2011-05-05

  Compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 , Q and W have the meanings indicated in Claim 1 , and precursors thereof are inhibitors of sphingosine kinase and can be employed, inter alia, for the treatment of tumours.

  式(I)的化合物中，其中R1、R2、R3、R4、R5、R6、R9、R10、R11、Q和W具有权利要求书中所示的含义，以及它们的前体是鞘氨醇激酶的抑制剂，可用于治疗肿瘤等用途。
• Sulfonyl Chlorides as Thiol Surrogates for Carbon–Sulfur Bond Formation: One-Pot Synthesis of Thioethers and Thioesters
  作者：Torsten Cellnik、Alan R. Healy

  DOI：10.1021/acs.joc.2c00330

  日期：2022.5.6

  A method to synthesize thioethers and thioesters directly from readily available sulfonyl chlorides is reported. We demonstrate that a transient intermediate formed during phosphine-mediated deoxygenation of sulfonyl chlorides can be trapped in situ by activated alcohols or carboxylic acids to effect carbon–sulfur bond formation. The method is operationally simple and tolerates a broad range of functional

  报道了一种直接从容易获得的磺酰氯合成硫醚和硫酯的方法。我们证明了在膦介导的磺酰氯脱氧过程中形成的瞬态中间体可以被活化的醇或羧酸原位捕获，从而影响碳硫键的形成。该方法操作简单并且可以容忍广泛的官能团。特别关注的是密集功能化天然产物和药物的后期多样化。
• Anti-biofilm Agents against <i>Pseudomonas aeruginosa</i>: A Structure–Activity Relationship Study of <i>C</i>-Glycosidic LecB Inhibitors
  作者：Roman Sommer、Katharina Rox、Stefanie Wagner、Dirk Hauck、Sarah S. Henrikus、Shelby Newsad、Tatjana Arnold、Thomas Ryckmans、Mark Brönstrup、Anne Imberty、Annabelle Varrot、Rolf W. Hartmann、Alexander Titz

  DOI：10.1021/acs.jmedchem.9b01120

  日期：2019.10.24

  bioavailable C-glycosidic inhibitors of the Pseudomonas aeruginosa lectin LecB with antibiofilm activity. They proved efficient in target binding, were metabolically stable, nontoxic, selective, and potent in inhibiting formation of bacterial biofilm. Here, we designed and synthesized six new carboxamides and 24 new sulfonamides for a detailed structure–activity relationship for two clinically representative

  生物膜的形成是抗菌素耐药性的关键机制。我们最近报道了铜绿假单胞菌的两种口服生物利用的C-糖苷抑制剂具有抗生物膜活性的凝集素LecB。他们证明了在靶标结合方面有效，在代谢上稳定，无毒，选择性强，并且在抑制细菌生物膜形成方面很有效。在这里，我们设计和合成了6种新的羧酰胺和24种新的磺酰胺，以详细说明两种具有临床代表性的LecB变体的结构-活性关系。与羧酰胺相比，磺酰胺通常表现出更高的抑制作用，这是根据晶体结构分析合理化的。噻吩磺酰胺的取代通过与亲脂性蛋白补丁的广泛接触而增加了结合。这些代谢稳定的化合物显示出对靶标的效力和生物膜抑制测定法的进一步提高。一般来说，